Fig. 1: Study design. | British Journal of Cancer

Fig. 1: Study design.

From: The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

Fig. 1

BID twice daily, PLD pegylated liposomal doxorubicin, QD daily. *The first two patients enrolled in Combination Module Cohort 1 and treated with AZD7648 20 mg QD for 28 days + PLD 40 mg/m2 on Day 1 of a 28-day cycle experienced DLTs. The SRC recommended a dose reduction to AZD7648 20 mg QD for 7 days and PLD 40 mg/m2 on Day 1 of a 28-day cycle for two patients. All patients in Cohort 2 received this same reduced dose of AZD7648 20 mg QD for 7 days and PLD 40 mg/m2 on Day 1 of a 28-day cycle as a separate cohort to confirm the safety before escalating to higher doses.

Back to article page